A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia
for Waldenström Macroglobulinemia
Drug: Pacritinib
1 location in Boston
Sponsor: Shayna Sarosiek, MD
Sex: All·Age: 18+
Code: NCT06986174·Phase 2·Recruiting